130701-19-8Relevant academic research and scientific papers
Lanthanide(III) complexes with a reinforced cyclam ligand show unprecedented kinetic inertness
Rodrguez-Rodrguez, Aurora,Esteban-G?mez, David,Tripier, Raphal,Tircs?, Gyula,Garda, Zoltn,T?th, Imre,De Blas, Andrs,Rodrguez-Blas, Teresa,Platas-Iglesias, Carlos
, p. 17954 - 17957 (2014)
Lanthanide(III) complexes of a cross-bridged cyclam derivative containing two picolinate pendant arms are kinetically inert in very harsh conditions such as 2 M HCl, with no dissociation being observed for at least 5 months. Importantly, the [Ln(dota)]su
Mono- and bis-alkylation of glyoxal-bridged tetraazamacrocycles using mechanochemistry
Abdulwahaab, Bassim H.,Burke, Benjamin P.,Domarkas, Juozas,Silversides, Jon D.,Prior, Timothy J.,Archibald, Stephen J.
, p. 890 - 898 (2016/02/18)
Glyoxal-bridged bisaminal tetraazamacrocyclic derivatives of 1,4,7,10-tetraazacyclododecane (cyclen) and 1,4,8,11-tetraazacyclotetradecane (cyclam) can be N-functionalized to incorporate coordinating groups or for conjugation to biomolecules. Herein, we p
NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF
-
Paragraph 0436; 0440, (2016/08/17)
The present invention provides a compound represented by the formula (1) or a salt thereof, or a complex of the compound or the salt with a metal, in the formula (1), A1 represents a chelate group; R1 represents a hydrogen atom or the like; R2 represents a hydrogen atom or the like; and Z1, Z2, Z3, Z4, and Z5 are the same or different and each represent a nitrogen atom or CR3 or the like wherein R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group or the like; L1 represents a group represented by the formula (3) wherein R13, R14, R15, and R16 are the same or different and each represent a hydrogen atom or the like; L2 represents an optionally substituted C1-6 alkylene group; and L3 represents an optionally substituted C1-6 alkylene group.
TREATMENT AGENT FOR DIAGNOSIS OR TREATMENT OF DISEASE ASSOCIATED WITH INTEGRIN
-
Paragraph 0489; 0490; 0494, (2018/10/03)
PROBLEM TO BE SOLVED: To provide a treatment agent for diagnosis or treatment of disease associated with integrin. SOLUTION: A treatment agent comprises a complex of a compound represented by formula (1) or salt thereof and metal. In the formula (1), A1 is a chelate group; R1 and R2 independently represent H, alkyl, or an amino protective group; Z1-Z5 independently represent N or CR3; R3 is H or a substituted/unsubstituted C1-6 alkyl group or the like; L1 is a group represented by formula (3); L2 and L3 independently represent a substituted/unsubstituted C1-6 alkylene group. In the formula (3), R13-R16 independently represent H, alkyl or the like. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT
Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes
Wong, Edward H.,Weisman, Gary R.,Hill, Daniel C.,Reed, David P.,Rogers, Mark E.,Condon, Jeffrey S.,Fagan, Maureen A.,Calabrese, Joseph C.,Lam, Kin-Chung,Guzei, Ilia A.,Rheingold, Arnold L.
, p. 10561 - 10572 (2007/10/03)
A series of 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane ligands, including the parent compound, N,N′-dialkyl variants, and the first N,N′-di-pendant-arm derivatives have been synthesized by a short, efficient, and conceptually novel approach. Their copper(I
Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands
Weisman, Gary R.,Wong, Edward H.,Hill, Daniel C.,Rogers, Mark E.,Reed, David P.,Calabrese, Joseph C.
, p. 947 - 948 (2007/10/03)
New cross-bridged tetraamine ligands (bicyclo[6.6.2], [6.5.2] and [5.5.2] systems) are synthesized; complexation of CuII and NiII demonstrates that the ligands coordinate selected metals in a cleft.
